In8Bio INAB
NASDAQ INAB
$1.11 +0.03 (+2.62%)
As of: Sep 10, 2026 · 1:54 PM EDT

In8Bio (INAB) Capital Leases (2021 - 2025)

In8Bio's (INAB) quarterly Capital Leases came in at $64000.0 in Q3 2025, down 83.96% year-over-year from $399000.0 in Q3 2024, and down 49.21% quarter-over-quarter from $126000.0 in Q2 2025.

Analysis

In8Bio (INAB) Capital Leases (2021 - 2025) Analysis & Trends

In8Bio has disclosed Capital Leases across 5 years of filings, most recently posting $64000.0 for Q3 2025.

  • In Q3 2025, Capital Leases fell 83.96% year-over-year to $64000.0; the TTM figure through Sep 2025 stood at $64000.0 (down 83.96% YoY), while the FY2024 annual figure was $295000.0, down 43.81% from the prior year.
  • Capital Leases came in at $64000.0 for Q3 2025 at In8Bio, down from $126000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $861000.0 in Q2 2023 to a low of $64000.0 in Q3 2025.
  • Average Capital Leases over 5 years is $386111.1, with a median of $347000.0 recorded in 2021.
  • Year-over-year, Capital Leases surged 937.31% in 2023 and plunged 83.96% in 2025.
  • Over 5 years, Capital Leases stood at $269000.0 in 2021, then jumped by 201.49% to $811000.0 in 2022, then tumbled by 35.27% to $525000.0 in 2023, then tumbled by 43.81% to $295000.0 in 2024, then sank by 78.31% to $64000.0 in 2025.
  • Per Business Quant data, the three most recent Capital Leases figures were $64000.0 in Q3 2025, $126000.0 in Q2 2025, and $189000.0 in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Krystal Biotech 10.21 Bn 9.36 Bn 112.79 Mn
2 CRISPR Therapeutics AG 5.04 Bn 5.04 Bn -
3 Iovance Biotherapeutics 3.64 Bn 3.35 Bn 55.72 Mn
4 Legend Biotech 3.54 Bn 2.58 Bn 251.50 Mn
5 uniQure 2.98 Bn 2.98 Bn 5.49 Mn
6 Beam Therapeutics 2.52 Bn 2.52 Bn -
7 Precigen 2.38 Bn 2.38 Bn 52.17 Mn
8 Sarepta Therapeutics 2.15 Bn 1.35 Bn 251.87 Mn
9 Vericel 1.93 Bn 1.77 Bn 56.40 Mn
10 In8Bio 21.58 Mn 21.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 64,000.00
Jun 30, 2025 126,000.00
Mar 31, 2025 189,000.00
Dec 31, 2024 295,000.00
Sep 30, 2024 399,000.00
Jun 30, 2024 526,000.00
Mar 31, 2024 351,000.00
Dec 31, 2023 525,000.00
Sep 30, 2023 695,000.00
Jun 30, 2023 861,000.00
Mar 31, 2023 664,000.00
Dec 31, 2022 811,000.00
Sep 30, 2022 67,000.00
Jun 30, 2022 132,000.00
Mar 31, 2022 201,000.00
Dec 31, 2021 269,000.00
Sep 30, 2021 343,000.00
Jun 30, 2021 432,000.00